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Objectives We sought to evaluate the cost-effectiveness of applying the JUPITER (Justification for the Use of statins in Pre-
vention: an Intervention Trial Evaluating Rosuvastatin) trial results into clinical practice.
Background The JUPITER trial found that rosuvastatin reduces vascular events in apparently healthy subjects with elevated
high-sensitivity C-reactive protein (hs-CRP) but normal low-density lipoprotein (LDL) cholesterol levels. The impli-
cations of expanding treatment recommendations based on these results have not been evaluated.
Methods We constructed a cost-effectiveness model of men 50 years and women 60 years with LDL cholesterol
levels of 130 mg/dl and no known cardiovascular disease. We compared: 1) hs-CRP testing followed by
rosuvastatin treatment for patients with hs-CRP levels 2.0 mg/l; and 2) usual care (i.e., no testing and no
treatment). Estimates of treatment effectiveness were based on the JUPITER trial and were varied in sensi-
tivity analyses.
Results Among patients with LDL 130 mg/dl and hs-CRP levels 2.0 mg/l, rosuvastatin had an incremental cost-
effectiveness of $25,198 per quality-adjusted life year (QALY) gained compared to usual care. If the effec-
tiveness of rosuvastatin were 50% of that observed in JUPITER, the incremental cost-effectiveness ratio
would increase to $50,871 per QALY. Implementing this strategy only in patients with a Framingham risk
score 10% yielded an incremental cost-effectiveness of $14,205 per QALY. Among such intermediate-risk
patients, a JUPITER-based strategy becomes cost-saving at a rosuvastatin price of $0.86 per day.
Conclusions Rosuvastatin treatment for JUPITER-eligible patients appears to be cost-effective, particularly among those with
a Framingham risk score 10%. (J Am Coll Cardiol 2011;57:784–91) © 2011 by the American College of
Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.07.059High-sensitivity C-reactive protein (hs-CRP) levels are
associated with cardiovascular risk and have been pro-
posed as a target for therapeutic intervention (1). The
JUPITER (Justification for the Use of statins in Preven-
tion: an Intervention Trial Evaluating Rosuvastatin)
study tested this association in apparently healthy sub-
jects with elevated hs-CRP levels (2.0 mg/l) and
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ment thresholds (130 mg/dl) (2). Patients randomized
to receive rosuvastatin had substantial reductions in their
risk of vascular events compared with those treated with
placebo (2,3).
See page 792
The implications of applying the JUPITER trial results
into routine practice are unclear. Although JUPITER found
impressive relative reductions in vascular events from rosu-
vastatin, the corresponding absolute benefits were modest
(4). Some have questioned whether the trial overestimated
treatment effects because it was terminated early for efficacy
(5). In addition, hs-CRP screening costs almost $20 per
test, rosuvastatin is available only as a brand-name agent,
and treatment for eligible patients would likely be continued
indefinitely. Accordingly, we evaluated the balance between
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February 15, 2011:784–91 Value of Rosuvastatin With Normal LDLpotential benefits and health care expenditures that would
result from adopting a strategy of hs-CRP testing followed
by rosuvastatin treatment, if indicated, for patients with
below-target LDL levels.
Methods
We constructed a model to evaluate 2 management strate-
gies in men 50 years and women 60 years with LDL
cholesterol levels of 130 mg/dl and no known cardiovas-
cular disease. The first strategy consisted of testing hs-CRP
followed by rosuvastatin for patients with hs-CRP levels
2.0 mg/l; the second strategy was usual care (no testing
and no treatment). The model (Fig. 1) simulates a cohort
of patients with an age, sex, and Framingham risk score
distribution based on the characteristics of the JUPITER
trial participants as they move, in annual cycles, through
health states that represent the occurrence of cardiovas-
cular, thrombotic, and statin-related adverse events as
well as death. Movement between these states is based on
transition probabilities observed in JUPITER, supple-
mented by an extensive review of the clinical literature.
The model was run separately for patients who undergo a
test-and-treat strategy and those who do not. Incremental
cost-effectiveness ratios were calculated as the difference in
costs for these 2 strategies divided by their difference in
quality-adjusted life-years (QALYs) produced. We did not
explicitly model health effects or costs for patients with low
hs-CRP levels because we assumed that in both treatment
Figure 1 Cost-Effectiveness Model Structure Comparing the Te
In each 1-year cycle, patients may experience 8 possible clinical events, resulting
the cycle, patients begin the next 1-year cycle in one of 33 possible health states
†There are a total of 33 health states depicting disease history and treatments. D
diabetes/no diabetes, and statin/no statin. ACS  acute coronary syndrome(s); C
tive protein; LDL  low-density lipoprotein; LFT  liver function test; MI  myocararms, these patients would not
receive a statin and thus their
outcomes and costs (other than
for initial hs-CRP screening in
the test-and-treat arm) would be
the same in both cases (i.e., were
nondifferential).
The analysis was conducted
over a lifetime time horizon from
a societal perspective, such that
all costs were included regardless
of payer. Future costs and life years were discounted at an
annual rate of 3%. We describe additional details about our
analytic strategy, including the sensitivity analyses we per-
formed, in the Online Appendix.
Data inputs for the model were published and unpub-
lished trial data obtained from the JUPITER investigators
and supplemented with other data from the published
literature (Table 1, Online Table 1).
HS-CRP SCREENING AND ROSUVASTATIN TREATMENT. Us-
ing data from JUPITER, we estimated that 50.3% of
patients with normal LDL levels have elevated hs-CRP
levels (6). This is consistent with other published estimates
(7). For patients with hs-CRP levels 2.0 mg/l, treatment
was assumed to consist of rosuvastatin 20 mg daily. Patients
in the usual care arm were assumed to initiate rosuvastatin
treatment only if they had myocardial infarction, unstable
angina hospitalization, stroke, or diabetes onset.
Abbreviations
and Acronyms
hs-CRP  high-sensitivity
C-reactive protein
LDL  low-density
lipoprotein
MI  myocardial infarction
QALY  quality-adjusted
life year
d-Treat Strategy and Usual Care
vival or death, and 1 or more complications. Based on their status at the end of
ical event and complication rates are modeled as a function of treatment status.
ions are: ACS/no prior ACS, prior stroke/no prior stroke, prior VTE/no prior VTE,
ardiovascular; DVT  deep venous thrombosis; hs-CRP  high sensitivity C-reac-
arction; PE  pulmonary embolism; VTE  venous thromboembolism.st-an
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Value of Rosuvastatin With Normal LDL February 15, 2011:784–91EVENT RATES WITH USUAL CARE. Rates of acute ischemic
events with usual care were obtained by applying the
observed age, sex, and Framingham risk score–specific event
rates in the placebo arm of the JUPITER trial to the first 5
years of follow-up. Mortality from other causes was esti-
mated by calibrating our model to annual survival estimates
from JUPITER. Event rates beyond the trial period were
estimated by multiplying the observed trial event rates by
age- and sex-specific multipliers obtained from longitudinal
cohort studies (8–10) to adjust for the aging of the study
population. Mortality from nonischemic causes was esti-
mated based on the age and sex distribution of surviving
Model VariablesTable 1 Model Variables
Parameter
Base Case
Estimate
Sensitivity Range
Tested
Prevalence of elevated hs-CRP 50% 25%–75%
Event rates with usual care
(per 100 person-yrs)*
Myocardial infarction 0.37 0.29–0.46
Hospitalization for unstable angina 0.14 0.10–0.21
Revascularization 0.71 0.60–0.84
Stroke 0.34 0.27–0.44
Venous thromboembolism 0.32 0.25–0.42
Physician-confirmed diabetes onset 1.04 0.90–1.10
Elevated liver enzymes 0.09 0.06–0.14
Myopathy 0.05 0.02–0.09
Effect of rosuvastatin on event rates
(hazard ratios)
Myocardial infarction 0.46 0.30–0.70
Hospitalization for unstable angina 0.59 0.32–1.1
Revascularization 0.54 0.41–0.72
Stroke 0.52 0.34–0.79
Venous thromboembolism 0.57 0.37–0.86
Diabetes 1.26 1.04–1.53
Elevated liver enzymes 1.24 0.65–2.34
Myopathy 1.11 0.45–2.74
Event-related mortality (in the year an
event occurs)†
Myocardial infarction 12.5% 6%–19%
Unstable angina 0.4% 0.2%–0.6%
Stroke 13.2% 7%–20%
Venous thromboembolism 4.5% 2%–7%
Utilities
Healthy 0.85 0.8–1
Vascular and adverse events‡
Myocardial infarction, unstable angina 0.88 0.80–0.93
Stroke 0.73 0.50–0.90
Diabetes 0.88 0.80–1.00
End-stage renal disease 0.61 0.45–0.75
Daily statin consumption 1.00 0.98–1.00
Treatment and monitoring costs
hs-CRP test $19 $0–$100
Liver function test $34 $17–$64
Rosuvastatin, 20 mg/day, daily cost
Brand name $3.63 $0.50–$4
Generic $1 $0.13–$1patients and age- and sex-specific U.S. life table data (11). tWe subtracted age- and sex-specific death rates from
ischemic causes, which were explicitly modeled in our
analysis, from the all-cause mortality rate (12).
EVENT RATES IN HS-CRP TEST-AND-TREAT ARM. In the
est-and-treat arm, event rates for patients with elevated
s-CRP levels who received rosuvastatin were calculated
sing outcome-specific hazard ratios for all pre-specified
rimary and secondary outcomes evaluated in JUPITER,
ncluding venous thromboembolism and diabetes. Because
he trial found no heterogeneity in treatment effects by age
nd sex, we used overall treatment effects. Although the trial
as terminated after a median follow-up of 1.9 years, many
atients were followed for longer, and the benefit of
osuvastatin appeared to increase over the 5-year trial period
13). Nevertheless, we assumed constant treatment effects
or the first 5 years of treatment. The effects of statin
herapy for patients with normal LDL and high hs-CRP
evels beyond this time period are unknown. Thus, in our
ase case analyses, we assumed that treatment effects per-
isted for 15 years at the level observed during the trial and
hen tapered off to no effect after 25 years of follow-up,
hich is a more conservative assumption than that made in
ther recent cost-effectiveness analyses of lipid-lowering
herapy (14). This assumption was tested in sensitivity
nalyses.
The JUPITER trial documented a 20% reduction in
ll-cause mortality in the test-and-treat arm (p  0.02), but
he cause of death was incompletely ascertained for some
ContinuedTable 1 Continued
Parameter
Base Case
Estimate
Sensitivity Range
Tested
Costs (in the year an event occurs)
Myocardial infarction $25,567 $13,000–$28,000
Unstable angina $8,510 $4,300–$13,000
Revascularization $30,209 $15,000–$45,000
Stroke $16,502 $8,300–$25,000
Pulmonary embolism $15,382 $7,500–$23,000
Deep vein thrombosis $1,058 $500–$1,600
Myopathy (including % resulting in
rhabdomyolysis)
$509 $200–$800
Elevated liver enzymes (including 0.5%
resulting in liver failure)
$325 $100–$500
Initial diagnosis of diabetes $117 $50–$200
Ongoing event costs (annual after first year)
Myocardial infarction, unstable angina $430 $200–$700
Stroke $17,158 $8,500–$26,000
Diabetes, including end stage renal
disease
$6,240 $3,000–$9,300
Discount rate, per year 3% 0–5%
Data sources for the model inputs are presented online in Online Table 1. *The rates are increased
after year 5 to reflect the aging of the study population. †Event-related mortality rates vary by age;
the presented values are average values for the initial JUPITER trial population. ‡Utilities for
patients with vascular and adverse events were calculated by multiplying utilities for the specific
event with age-specific utilities for healthy individuals. For example, the utility of having a
myocardial infarction is equal to 0.85  0.88  0.75.
hs-CRP  high sensitivity C-reactive protein; JUPITER  Justification for the Use of statins in
revention: an Intervention Trial Evaluating Rosuvastatin.rial participants who died after their primary outcome event
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February 15, 2011:784–91 Value of Rosuvastatin With Normal LDL(for example, patients who died after having a stroke). As a
result, a model that measured the benefit of rosuvastatin on
mortality entirely in terms of reductions in ischemic event
related mortality underestimates the total benefit of this
treatment on all-cause mortality. To adjust for this, we
calibrated death rates for the test-and-treat arm to the actual
rates of all-cause mortality in JUPITER observed during the
first 5 years of follow-up. After this period, we conserva-
tively applied the hazard ratios described in JUPITER
without any correction factor.
COSTS. The cost of hs-CRP screening was based on the
urrent Medicare payment rate for this test (15). Because we
valuated a cohort of patients already identified as having
DL levels below 130 mg/dl, we did not include the cost of
holesterol testing in our model. All patients in the test-
Event Rates Estimated by the Cost-EffectivenessModel Compared With the JUPITER Trial ResultsTable 2 v nt Rates Estimated by the Co t-EffectivenessModel Compared With the JUPITER Trial Results
Outcome
Number of Events With
Usual Care
Number of Events With
hs-CRP Screening and
Rosuvastatin Treatment
if Elevated
JUPITER
Estimated
by Model* JUPITER
Estimated
by Model*
MI 68 68 31 31
Unstable angina 27 26 16 15
Stroke 64 62 33 32
Revascularization 131 129 71 70
*Model event counts are for the mean follow-up in JUPITER and were estimated assuming that
patients were censored for occurrence of the primary event.
MI  myocardial infarction; other abbreviations as in Table 1.
Figure 2 Event-Free Survival Predicted by the Cost-Effectivenes
The solid black (test-and-treat) and dashed gray (usual care) lines represent the m
(placebo) represent the observed event-free survival in JUPITER (Justification for thnd-treat strategy, including those ultimately found to have
level2.0 mg/l, were assumed to undergo hs-CRP testing
nd, therefore, to incur the cost of the test. In the base case
nalysis, we calculated rosuvastatin costs from a major
nline pharmacy (16). The cost until 2016 (i.e., the first 7
ears of the model) was assumed to be the quoted price for
randed rosuvastatin ($3.63/day). After patent expiration,
e assumed that the generic rosuvastatin price would be
omparable to that of generic simvastatin beginning in 2018
$1/day), and halfway between branded Crestor and generic
imvastatin (80 mg/day) prices during 2017 ($2.32/day).
osuvastatin-treated patients were assumed to receive liver
unction testing at treatment initiation, 1 month later, and
nce per year thereafter.
We calculated the costs of acute clinical events by summing
he costs for acute hospitalization, physician services, medica-
ion use, and post-acute care for each outcome. Costs of
ngoing care in cycles in which no acute event occurred were
ncluded for patients with a stroke, MI, angina, or diabetes. All
osts were expressed in 2009 U.S. dollar values.
esults
or a cohort of men 50 years and older and women 60 years
nd older without known cardiovascular disease and LDL
evels of 130 mg/dl, the model closely estimated the
umber of outcome events (Table 2) and rate of 5-year
ll-cause mortality (Fig. 2) observed in both arms of the
UPITER trial.
del Compared With the JUPITER Trial Results
estimates. The red diamonds (rosuvastatin) and blue squares
of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).s Mo
odel
e Use
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Value of Rosuvastatin With Normal LDL February 15, 2011:784–91Base care results. Patients treated with usual care (i.e., no
hs-CRP testing or treatment) were estimated to have an
average quality-adjusted life expectancy of 10.29 QALYs,
and associated health care costs of $19,717 (Table 3).
A strategy of hs-CRP testing followed by rosuvastatin
treatment for patients with hs-CRP levels 2.0 mg/l
resulted in an average quality-adjusted life expectancy of
Base Case ResultsTable 3 Base Case Results
Usual Care
hs-CRP Screening
and Rosuvastatin
Treatment if
Elevated Difference
Costs, $*
Screening and treatment $1,032 $11,366 $10,334
Vascular events $12,241 $8,077 $4,164
Adverse events $6,444 $8,173 $1,729
Total $19,717 $27,616 $7,899
Effectiveness, QALY* 10.29 10.61 0.31
Incremental cost-effectiveness
ratio ($/QALY)
— — $25,198
Values are in U.S. dollars. *All future costs and QALYs were discounted at a rate of 3% per year.
QALY  quality-adjusted life year; other abbreviations as in Table 1.
Figure 3 1-Way Sensitivity Analyses
Each bar represents the incremental cost-effectiveness ratio of the test-and-treat s
depicts the incremental cost-effectiveness ratio when all parameters are set at th
effects, “min” and “max” represent the weakest and strongest effects, respective
For the duration of treatment effects, “min” represents the scenario in which the
in the “max” scenario, full treatment effects were assumed to persist for 25 years a
multiples of base case values. ***Utilities for patients with vascular and adverse eve
for healthy individuals. For example, the utility of having an MI is equal to 0.85  0.810.61 QALYs and costs of $27,616. As a consequence, this
strategy had an incremental cost-effectiveness of $25,198
per QALY gained, compared with usual care. The cost per
life year gained was $22,160.
Sensitivity analyses. The base case results were robust to
alterations in many model parameters (Fig. 3). Assuming a
reduced effectiveness of rosuvastatin that is at the most
unfavorable 95% confidence limit for the point estimates
in JUPITER (for example, a hazard ratio of 0.70 for the
reduction in myocardial infarction instead of the observed
hazard ratio of 0.46) resulted in an incremental cost-
effectiveness ratio of $57,503 per QALY. Limiting the
impact of the test-and-treat strategy on mortality to that
resulting directly from its impact on preventing vascular
events (i.e., removing the apparent effect of rosuvastatin on
noncardiovascular mortality) yielded an incremental cost-
effectiveness ratio of $39,392. If the effect of rosuvastatin
observed in JUPITER only persisted for 5 years with no
subsequent effect, the cost-effectiveness of hs-CRP testing
would be $62,146 per QALY. In contrast, if the full effect
of treatment persisted for 25 years and then tapered off to no
effect by 35 years, the cost-effectiveness of the test-and-treat
y for different assumptions concerning the parameter listed. The vertical line
e case values (listed in parentheses beside the parameter name). *For statin
ed on the 95% confidence interval of the point estimates observed in JUPITER.
effects from the JUPITER trial were assumed to persist for 5 years only, whereas
n taper off over the subsequent 10 years. **Sensitivity analyses values represent
re calculated by multiplying utilities for the specific event with age-specific utilities
75. QALY  quality-adjusted life year; other abbreviations as in Figure 1.trateg
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February 15, 2011:784–91 Value of Rosuvastatin With Normal LDLstrategy would be $20,962 per QALY. In JUPITER, a
greater proportion of myocardial infarctions were fatal
among patients treated with rosuvastatin as compared pla-
cebo; incorporating this differential fatality rate into our
model resulted in an incremental cost-effectiveness ratio of
$31,559 per QALY. Restricting the hs-CRP test-and-treat
strategy to patients with a Framingham risk score predicting
a10% risk of myocardial infarction or coronary death over
10 years would lead to an incremental cost-effectiveness
ratio of $14,205 per QALY. The cost-effectiveness of
restricting rosuvastatin to patients with Framingham risk
scores of10% would be $54,961 per QALY. If consuming
osuvastatin on a daily basis were associated with a utility of
.98, a JUPITER-based strategy would have a cost-
ffectiveness of $62,633 per QALY.
The results of 2-way sensitivity analyses are shown in
igure 4. If treatment efficacy were 50% of JUPITER
stimates but was restricted to patients with a Framingham
isk score 10%, it would have an incremental cost-
effectiveness ratio of $34,190 per QALY (Fig. 4A). If statin
treatment were 50% as effective as observed in JUPITER
but statin costs were $1 per day, the test-and-treat strategy
would be associated with an incremental cost-effectiveness
of $22,874 per QALY for all patients (Fig. 4C) and $13,509
Figure 4 2-Way Sensitivity Analyses
Assessment of the impact of treatment efficacy and Framingham risk score (A), ro
price for all patients (C), and treatment efficacy and rosuvastatin price for patient
at $1 is the result of the assumed fall in the price of rosuvastatin to this level wh
Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rper QALY in patients with a Framingham risk score 10%
(Fig. 4D). At statin costs less than $0.11 per day, the
test-and-treat strategy would be cost-saving for intermediate-
risk patients even if treatment were only 50% as effective as
observed in JUPITER. If testing and treatment were restricted
to patients with a Framingham risk score of 10%, and the
aily cost of rosuvastatin were reduced to$0.86, this strategy
ould improve outcomes and would save money compared to
sual care (Fig. 4B).
Figure 5 presents the results of our probabilistic sensitiv-
ty analysis. The mean cost-effectiveness from these simu-
ations was $27,575 per QALY with a 95% credible interval
f $10,400 to $62,782 per QALY. Ninety-four percent of
he probabilistic simulations produce cost-effectiveness ra-
ios below a willingness to pay of $50,000 per QALY,
uggesting that at this threshold, there is a high likelihood
hat the intervention would be cost-effective.
iscussion
his analysis found that hs-CRP testing and rosuvastatin
reatment for hs-CRP 2.0 mg/l in healthy individuals with
DL levels 130 mg/dl is cost-effective compared with
onventionally used thresholds of $50,000 to $100,000 per
tatin cost and Framingham risk score (B), treatment efficacy and rosuvastatin
a Framingham risk score of 10% (D). In the top right panel, the inflection point
erics become available. ICER  incremental cost-effectiveness ratio; JUPITER 
tatin; QALY  quality-adjusted life year.suvas
s with
en gen
osuvas
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Value of Rosuvastatin With Normal LDL February 15, 2011:784–91QALY (17). This strategy compares favorably with the cost-
effectiveness of fully implementing existing National Choles-
terol Education Program (NCEP) lipid-lowering guidelines,
which has been estimated at $42,000 per QALY (14). Hs-
CRP testing and rosuvastatin treatment, if indicated, appear
most cost-effective for those with Framingham risk scores of
10%. This finding is consistent with recommendations from
the Canadian Cardiovascular Society (18), the U.S. National
Academy of Clinical Biochemistry (19), and the American
Heart Association/Centers for Disease Control and Preven-
tion (20), that a test-and-treat strategy be restricted to
intermediate-risk patients. In contrast, the U.S. Preventive
Service Task Force has recommended against a JUPITER-
based strategy even in intermediate-risk patients, citing the
absence of cost-effectiveness data and uncertainty about
whether statin treatment based on hs-CRP testing provides
incremental value beyond treatment based on Framingham
risk assessment alone (21). Our results may help to clarify some
of these uncertainties and inform the ongoing evolution of
lipid-lowering treatment guidelines.
Our analysis used statin effect estimates from the
JUPITER trial, which are higher than those seen in other
statin trials (22). It has been argued that the JUPITER
results overestimate true treatment effects because the trial
was stopped early for efficacy (5). Others contend that
clinical trials with principled monitoring plans yield valid
estimates of treatment effects (23). Because of the uncer-
tainly surrounding this influential model parameter, we
repeated our analyses using more conservative assumptions
of treatment effects and found incremental cost-effectiveness
ratios that remain below typical willingness-to-pay thresholds.
Only 1 prior estimate of the cost-effectiveness of statin
treatment for patients with elevated hs-CRP has been pub-
Figure 5 Probabilistic Sensitivity Analyses
The sensitivity ranges tested for each variable are shown in Table 1. Each
point represents the incremental cost and incremental effectiveness of a test-
and-treat strategy versus usual care for one simulation. The red dashed line
depicts a societal willingness to pay threshold of $50,000 per quality-adjusted
life year (QALY).lished (24). This analysis found cost-effectiveness ratios of$48,100 and $94,400 per QALY for 58-year-old men and
women, respectively, who were on average at lower baseline
risks than the population we modeled. The study relied on
statin treatment effects derived from post hoc analyses, which
found smaller reductions in the risk of stroke from statins than
was observed in JUPITER and did not consider other impor-
tant pre-specified outcomes, such as venous thromboembolism
or diabetes. Sensitivity analyses altering the model assumptions
to be more similar to those that we used yielded results that are
very consistent with ours.
As expected, rosuvastatin treatment for patients with an
elevated hs-CRP level becomes more cost-effective as the
price of rosuvastatin is lowered. If a JUPTER-based strategy
were restricted to intermediate-risk patients, it dominates
usual care (i.e., improves health outcomes and reduces
overall spending) at rosuvastatin prices below $0.86 per day.
This price is similar to that of simvastatin and is more than
those of pravastatin and lovastatin, which are both widely
available in the U.S. for as little as $10 for a 90-day supply
(i.e., $0.11 per day). Of course, the JUPITER trial specif-
ically evaluated rosuvastatin, and the efficacy of other statins
in this setting remains unclear. Lovastatin may reduce
vascular events in patients with low LDL and elevated
hs-CRP levels to a similar degree to those observed in
JUPITER, but this observation was based on post hoc data
(25). Even if other statins were less effective than rosuvas-
tatin, our analysis suggests their use could still be cost-
effective, if not cost-saving, because of their much lower
cost. For example, if 1 of the generically available statins
were only 75% as effective as rosuvastatin, its use as part of
a test-and-treat strategy in patients with a Framingham risk
score of 10% would be cost-saving at a daily drug cost of
$0.49 per day. This finding is very consistent with cost-
effectiveness estimates of generic simvastatin based upon
results from the Heart Protection Study (26).
Study limitations. First, we did not evaluate the cost-
effectiveness of treating all patients with below-target cho-
lesterol levels. This practice is not recommended by current
guidelines, and we sought to evaluate the next incremental
step in cardiovascular risk reduction. Further, no random-
ized trial has prospectively assessed the value of statin
treatment for patients with low LDL and low hs-CRP
levels, and post hoc data suggest that these patients do not
benefit from statin treatment (25). Accordingly, Blake et al.
(24) found that treating all patients with normal LDL levels
was associated with incremental cost-effectiveness ratios
that were much less favorable than those we observed
($100,000 per QALY compared with usual care and
$500,000 per QALY compared with a test-and-treat
strategy).
Second, we relied on data from the JUPITER trial to
build our model (2). This trial did not provide all of the
necessary data to perform a cost-effectiveness analysis of a
test-and-treat strategy from a societal perspective over a
lifetime horizon. In addition to uncertainty surrounding the
treatment effects observed in JUPITER, data on resource
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
791JACC Vol. 57, No. 7, 2011 Choudhry et al.
February 15, 2011:784–91 Value of Rosuvastatin With Normal LDLutilization, health care costs, and utilities were not prospec-
tively collected. It is reassuring that our results were robust
to our modeling assumptions. Third, most patients in the
U.S. receive pharmacy benefits through third-party insurers
who negotiate substantial rebates from drug manufacturers.
Because the magnitude of these discounts is not publicly
disclosed, we relied on retail prices charged to individual
consumers, which tend to be the highest prices paid for a
given drug. This would lead to an underestimation of the
cost-effectiveness of an hs-CRP test-and-treat strategy.
Conclusions
Our analysis demonstrates that a strategy of rosuvastatin
treatment for apparently healthy patients with low LDL and
elevated hs-CRP levels is cost-effective relative to typical
willingness-to-pay thresholds. As expected, more conserva-
tive estimates of the treatment effects from the JUPITER
trial lead to less attractive cost-effectiveness ratios, although
even these appear to be relatively cost-effective. The value of
this strategy appears greatest for patients with Framingham
risk scores 10%, and thus our findings are consistent with
several current practice guidelines. If the price of rosuvas-
tatin were reduced to $0.86, treatment of intermediate-risk
individuals with elevated hs-CRP levels may not only be
cost-effective, but also cost-saving.
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APPENDIX
For an expanded Methods section and a supplemental table,
please see the online version of this article.
